PRECIGEN, INC. Increase (Decrease) in Accounts Payable
PRECIGEN, INC. (PGEN) reported Increase (Decrease) in Accounts Payable of -$4.43 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2019-11-12
- PRECIGEN, INC. increase (decrease) in accounts payable for the quarter ending 2019-09-30 was -$746.00K.
- PRECIGEN, INC. increase (decrease) in accounts payable for the quarter ending 2019-06-30 was -$2.45M, a 927.36% decline year-over-year.
- PRECIGEN, INC. increase (decrease) in accounts payable for the quarter ending 2019-03-31 was -$1.24M.
- PRECIGEN, INC. increase (decrease) in accounts payable for the quarter ending 2018-12-31 was $5.41M, a 1428.53% increase year-over-year.
- PRECIGEN, INC. increase (decrease) in accounts payable for fiscal 2018 was $4.68M.
- PRECIGEN, INC. increase (decrease) in accounts payable for fiscal 2017 was -$3.40M, a 194.03% decline from fiscal 2016.
- PRECIGEN, INC. increase (decrease) in accounts payable for fiscal 2016 was $3.62M.
- PRECIGEN, INC. increase (decrease) in accounts payable for fiscal 2015 was -$3.26M, a 357.74% decline from fiscal 2014.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2019-09-30 | -$746.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$3.19M derived: sum of 2 quarters · filed 2019-11-12 | -$4.43M 10-Q · filed 2019-11-12 | $979.00K derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-06-30 | -$2.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$3.69M 10-Q · filed 2019-08-09 | $1.73M derived: sum of 3 quarters · filed 2019-08-09 | $1.46M derived: sum of 4 quarters · filed 2019-11-12 |
| 2019-03-31 | -$1.24M 10-Q · filed 2019-05-09 | $4.17M derived: sum of 2 quarters · filed 2019-05-09 | $3.91M derived: sum of 3 quarters · filed 2019-11-12 | $4.21M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-12-31 | $5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $5.15M derived: sum of 2 quarters · filed 2019-11-12 | $5.44M derived: sum of 3 quarters · filed 2019-11-12 | $4.68M 10-K · filed 2019-03-01 |
| 2018-09-30 | -$263.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $33.00K derived: sum of 2 quarters · filed 2019-11-12 | -$731.00K 10-Q · filed 2019-11-12 | -$377.00K derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $296.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$468.00K 10-Q · filed 2019-08-09 | -$114.00K derived: sum of 3 quarters · filed 2019-08-09 | -$78.00K derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | -$764.00K 10-Q · filed 2019-05-09 | -$410.00K derived: sum of 2 quarters · filed 2019-05-09 | -$374.00K derived: sum of 3 quarters · filed 2019-05-09 | -$3.18M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $390.00K derived: sum of 2 quarters · filed 2019-03-01 | -$2.41M derived: sum of 3 quarters · filed 2019-03-01 | -$3.40M 10-K · filed 2019-03-01 |
| 2017-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$2.77M derived: sum of 2 quarters · filed 2018-11-08 | -$3.76M 10-Q · filed 2018-11-08 | -$3.04M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-06-30 | -$2.80M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-13 | -$3.79M 10-Q · filed 2018-08-13 | -$3.08M derived: sum of 3 quarters · filed 2019-03-01 | -$3.01M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-03-31 | -$990.00K 10-Q/A · filed 2018-08-13 | -$273.00K derived: sum of 2 quarters · filed 2019-03-01 | -$206.00K derived: sum of 3 quarters · filed 2019-03-01 | $235.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2016-12-31 | $717.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $784.00K derived: sum of 2 quarters · filed 2019-03-01 | $1.23M derived: sum of 3 quarters · filed 2019-03-01 | $3.62M 10-K · filed 2019-03-01 |
| 2016-09-30 | $67.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $508.00K derived: sum of 2 quarters · filed 2017-11-09 | $2.90M 10-Q · filed 2017-11-09 | $3.20M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $441.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $2.83M 10-Q · filed 2017-08-09 | $3.13M derived: sum of 3 quarters · filed 2018-03-01 | -$304.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $2.39M 10-Q · filed 2017-05-10 | $2.69M derived: sum of 2 quarters · filed 2018-03-01 | -$745.00K derived: sum of 3 quarters · filed 2018-03-01 | -$1.54M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$3.14M derived: sum of 2 quarters · filed 2018-03-01 | -$3.94M derived: sum of 3 quarters · filed 2018-03-01 | -$3.26M 10-K · filed 2018-03-01 |
| 2015-09-30 | -$3.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$4.23M derived: sum of 2 quarters · filed 2016-11-09 | -$3.56M 10-Q · filed 2016-11-09 | -$1.10M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | -$797.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$125.00K 10-Q · filed 2016-08-09 | $2.34M derived: sum of 3 quarters · filed 2017-03-01 | $802.00K derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $672.00K 10-Q · filed 2016-05-10 | $3.13M derived: sum of 2 quarters · filed 2017-03-01 | $1.60M derived: sum of 3 quarters · filed 2017-03-01 | $1.42M derived: sum of 4 quarters · filed 2017-03-01 |
| 2014-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $927.00K derived: sum of 2 quarters · filed 2017-03-01 | $750.00K derived: sum of 3 quarters · filed 2017-03-01 | $1.27M 10-K · filed 2017-03-01 |
| 2014-09-30 | -$1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$1.71M derived: sum of 2 quarters · filed 2015-11-09 | -$1.20M 10-Q · filed 2015-11-09 | -$1.42M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$177.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $339.00K 10-Q · filed 2015-08-10 | $114.00K derived: sum of 3 quarters · filed 2016-02-29 | -$426.00K derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $516.00K 10-Q · filed 2015-05-11 | $291.00K derived: sum of 2 quarters · filed 2016-02-29 | -$249.00K derived: sum of 3 quarters · filed 2016-02-29 | $539.00K derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$225.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$765.00K derived: sum of 2 quarters · filed 2016-02-29 | $23.00K derived: sum of 3 quarters · filed 2016-02-29 | -$43.00K 10-K · filed 2016-02-29 |
| 2013-09-30 | -$540.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $248.00K derived: sum of 2 quarters · filed 2014-11-13 | $182.00K 10-Q · filed 2014-11-13 | -$63.00K derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-06-30 | $788.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $722.00K 10-Q · filed 2014-08-14 | $477.00K derived: sum of 3 quarters · filed 2015-03-02 | $75.00K derived: sum of 4 quarters · filed 2015-03-02 |
| 2013-03-31 | -$66.00K 10-Q · filed 2014-05-09 | -$311.00K derived: sum of 2 quarters · filed 2015-03-02 | -$713.00K derived: sum of 3 quarters · filed 2015-03-02 | |
| 2012-12-31 | -$245.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$647.00K derived: sum of 2 quarters · filed 2015-03-02 | -$1.23M 10-K · filed 2015-03-02 | |
| 2012-09-30 | -$402.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-07 | -$984.00K 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | -$582.00K 10-Q/A · filed 2013-10-21 | |||
| 2011-12-31 | -$388.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |